Skip to main content
SpringerLink
Log in

Glutathione S-Transferase P1 Ile105Val Polymorphism is Associated with Haematological Toxicity in Elderly Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Background: Increasing evidence suggests that common gene polymorphisms may influence the toxicity of various cytotoxic agents used in the treatment of cancer.

Objective: To evaluate the predictive value of acute toxicity of methylenetetrahydrofolate reductase 677T polymorphism, glutathione S-transferase P1 (GSTP1) substitution of isoleucine with valine at codon 105 (Ile105Val) polymorphism and the tandem repeat polymorphism in the thymidylate synthase gene promoter in elderly patients with rectal cancer receiving preoperative chemoradiotherapy (CRT).

Method: From 1994 to 2002, 166 Caucasian patients underwent surgery following CRT for mid-low rectal cancer at a single institution, 42 (male-to-female ratio, 25:17) of whom were aged ≥65 years (median age 70 years, range 65–79). The pre-treatment clinical stage was tumour (T) stage 3–4 in 38 patients and node (N)-positive in 29 patients. Patients received external-beam radiotherapy with conventional fractionation and fluorouracil-based chemotherapy. Blood samples were used to extract and amplify DNA. Gene polymorphisms were determined by polymerase chain reaction and restriction enzyme digestion. Acute toxicity to preoperative therapy was reported according to the National Cancer Institute Common Toxicity Criteria, version 2. Univariate and multivariate analyses were performed using one-way analysis of variance and linear regression, respectively.

Results: Haematological toxicity (grade 1–2) was observed in 15 of 40 patients for whom toxicity data were available and gastrointestinal toxicity (grade 1–4) in 24 of these same 40 patients. At univariate analysis, female sex (p = 0.036) and GSTP1 Ile105Val (p = 0.0376) were associated with haematological toxicity. At multivariate analysis, GSTP1 Ile105Val polymorphism (p = 0.041) was the only factor found to be associated with haematological toxicity. Patients carrying the Val/Val genotype in the GSTP1 gene had a lower risk of haematological toxicity (odds ratio = 0.322, 95% CI 0.101, 0.957) than patients with the Ile/Ile genotype.

Conclusion: GSTP1 Ile105Val polymorphism is a promising marker of potential haematological toxicity in elderly patients with rectal cancer receiving preoperative CRT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. EUCAN. Cancer incidence, mortality and prevalence in the European Union: 1998 estimates [online]. Available from URL: http://www-dep.iarc.fr/eucan/eucan.htm [Accessed 2008 Apr 1]

  2. Grobovsky L, Kaplon M, Krozser-Hamati A, et al. Features of cancer in frail elderly patients (pts) (85 years of age) [abstract no. 2469]. Proc Am Soc Clin Oncol 2000; 19: 139

    Google Scholar 

  3. Pucciarelli S, Friso ML, Toppan P, et al. Preoperative combined radiotherapy and chemotherapy for middle and lower rectal cancer: preliminary results. Ann Surg Oncol 2000; 7(1): 38–44

    Article  PubMed  CAS  Google Scholar 

  4. The Advanced Colorectal Meta-Analysis Project. Modulation of fluorouracil with leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903

    Google Scholar 

  5. O’Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. New Engl J Med 1994; 331: 502–7

    Article  PubMed  Google Scholar 

  6. Sobrero A, Guglielmi A, Cirillo M, et al. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. Br J Cancer 2001; 84(8): 1023–8

    Article  PubMed  CAS  Google Scholar 

  7. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345(15): 1091–7

    Article  PubMed  CAS  Google Scholar 

  8. The Advanced Colorectal Cancer Meta-Analysis Project. Metaanalysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960–9

    Google Scholar 

  9. The Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301–8

    Google Scholar 

  10. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053–71

    Article  PubMed  CAS  Google Scholar 

  11. Hessman O, Bergkvist L, Strom S. Colorectal cancer in patients over 75 years of age: determinants of outcome. Eur J Surg Oncol 1997; 23(1): 13–9

    Article  PubMed  CAS  Google Scholar 

  12. Koperna T, Kisser M, Schulz F. Hepatic resection in the elderly. World J Surg 1998; 22(4): 406–12

    Article  PubMed  CAS  Google Scholar 

  13. Balducci L, Yates G. General guidelines for the management of older patients with cancer. Oncology 2000; 14: 221–7

    PubMed  CAS  Google Scholar 

  14. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001; 1: 99–108

    Article  PubMed  CAS  Google Scholar 

  15. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003; 3: 912–20

    Article  PubMed  CAS  Google Scholar 

  16. Nagasubramanian R, Innocenti F, Ratain MJ, et al. Pharmacogenetics in cancer treatment. Ann Rev Med 2003; 54: 437–52

    Article  PubMed  CAS  Google Scholar 

  17. Jakobsen A, Nielsen JN, Gyldenkerne N, et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365–9

    Article  PubMed  CAS  Google Scholar 

  18. Chiusolo P, Reddiconto G, Casorelli I, et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002; 13(12): 1915–8

    Article  PubMed  CAS  Google Scholar 

  19. Stoehlmacher J, Park DJ, Zhang W, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94: 936–42

    Article  PubMed  CAS  Google Scholar 

  20. Edvardsen H, Kristensen VN, Grenaker Alnaes GI, et al. Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy. Int J Radiat Oncol Biol Phys 2007; 67(4): 1163–71

    Article  PubMed  CAS  Google Scholar 

  21. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on RT. Int J Radiat Oncol Biol Phys 2000; 47: 13–47

    Article  PubMed  CAS  Google Scholar 

  22. Van Triest B, Peters GJ. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 1999; 57: 179–94

    Article  PubMed  Google Scholar 

  23. Agostini M, Pucciarelli S, Calandra P, et al. Genetic heterogeneity of variable number tandem repeats in thymidylate synthase gene in colorectal cancer patients. Int J Biol Markers 2004; 19(4): 332–6

    PubMed  CAS  Google Scholar 

  24. Terrazzino S, Agostini M, Pucciarelli S, et al. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenet Genomics 2006; 16(11): 817–24

    Article  PubMed  CAS  Google Scholar 

  25. Harries LW, Stubbins MJ, Forman D, et al. Identification of genetic polymorphisms at the glutathione S-transferase P1 locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997; 18: 641–4

    Article  PubMed  CAS  Google Scholar 

  26. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5FU chemotherapy. Pharmacogenomics J 2001; 1(1): 65–70

    Article  PubMed  CAS  Google Scholar 

  27. Cohen V, Panet-Raymond V, Sabbaghian N, et al. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9: 1611–5

    PubMed  CAS  Google Scholar 

  28. Mannervik B, Alin P, Guthenberg C, et al. Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc Natl Acad Sci U S A 1985; 82: 7202–6

    Article  PubMed  CAS  Google Scholar 

  29. Moscow JA, Fairchild CR, Madden MJ, et al. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 1989; 49: 1422–8

    PubMed  CAS  Google Scholar 

  30. Ban N, Takahashi Y, Takayama T, et al. Transfection of glutathione S-transferase (GST)-P1 antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res 1996; 56: 3577–82

    PubMed  CAS  Google Scholar 

  31. O’Brien M, Kruh GD, Tew KD. The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther 2000; 294: 480–7

    PubMed  Google Scholar 

  32. Tsuchida S, Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 1992; 27: 337–84

    Article  PubMed  CAS  Google Scholar 

  33. Watson MA, Stewart RK, Smith GB, et al. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 275–80

    Article  PubMed  CAS  Google Scholar 

  34. Srivastava SK, Singhal SS, Hu X, et al. Differential catalytic efficiency of allelic variants of human glutathione S-transferase P1 in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys 1999; 366: 89–94

    Article  PubMed  CAS  Google Scholar 

  35. Sweeney C, McClure GY, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 2000; 60: 5621–4

    PubMed  CAS  Google Scholar 

  36. Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 50 tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63(11): 2898–904

    PubMed  CAS  Google Scholar 

  37. Dotor E, Cuatrecases M, Martinez-Iniesta M. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006; 24(10): 1603–11

    Article  PubMed  CAS  Google Scholar 

  38. Toffoli G, Russo A, Innocenti F, et al. Effect of methylenetetrahydrofolate reductase 677C—>T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003; 103: 294–9

    Article  PubMed  CAS  Google Scholar 

  39. Pasetto LM, Friso ML, Pucciarelli S, et al. Rectal cancer neoadjuvant treatment in elderly patients. Anticancer Res 2006; 26: 3913–24

    PubMed  Google Scholar 

Download references

Acknowledgements

This study, conducted in Padova (Italy), was partially supported by grants from the Italian Ministry of Health (Programma speciale ex. art.12, 2004), AIRC (Associazione Italiana Ricerca Cancro). The authors have no conflicts of interest that are directly relevant to the content of this study. The authors are grateful to Miss Marta Briarava for collecting and managing clinical and research data, and to Antonette Leon for her assistance with the English language.

Author information

Authors and Affiliations

  1. Clinica Chirurgica II, Department of Oncological and Surgical Sciences, University of Padova, Via Giustiniani 2, 35128, Padova, Italy

    Marco Agostini,  Salvatore Pucciarelli, Alessandro Ambrosi, Chiara Bedin, Francesca Galdi, Emanuele Urso, Mario Lise & Donato Nitti

  2. Oncologia Medica 2, Istituto Oncologico Veneto IRCCS, Padova, Italy

    Lara Maria Pasetto

  3. Research & Innovation Laboratories, Padova, Italy

    Salvatore Terrazzino & Alberta Leon

  4. Studio Nutrizione & Benessere, Como, Italy

    Salvatore Terrazzino

  5. Istituto Oncologico Veneto IRCCS, Padova, Italy

    Alessandro Ambrosi

  6. Radioterapia, Istituto Oncologico Veneto IRCCS, Padova, Italy

    Maria Luisa Friso

  7. Anatomia Patologica, Istituto Oncologico Veneto IRCCS, Padova, Italy

    Claudia Mescoli

  8. Chirurgia Oncologica I, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy

    Mario Lise

Authors
  1. Marco Agostini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lara Maria Pasetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salvatore Pucciarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Salvatore Terrazzino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alessandro Ambrosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chiara Bedin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francesca Galdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maria Luisa Friso
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Claudia Mescoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Emanuele Urso
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Alberta Leon
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Mario Lise
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Donato Nitti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Salvatore Pucciarelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agostini, M., Pasetto, L.M., Pucciarelli, S. et al. Glutathione S-Transferase P1 Ile105Val Polymorphism is Associated with Haematological Toxicity in Elderly Rectal Cancer Patients Receiving Preoperative Chemoradiotherapy. Drugs Aging 25, 531–539 (2008). https://doi.org/10.2165/00002512-200825060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200825060-00006

Keywords

Search

Navigation